Tirzepatide
SURMOUNT-4
Eli Lilly · Phase 3 · Completed · Enrollment 783
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Tirzepatide (lead-in) | 278 participants | 128 participants | 165 participants | n/r | 1 |
| Tirzepatide MTD | 27 participants | 18 participants | 36 participants | n/r | 1 |
| Placebo | 9 participants | 4 participants | 16 participants | n/r | 1 |
A count stays a count. This page does not turn a count into a percent.